Equities analysts expect Iovance Biotherapeutics Inc (NASDAQ:IOVA) to announce earnings per share (EPS) of ($0.42) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Iovance Biotherapeutics’ earnings, with estimates ranging from ($0.45) to ($0.40). Iovance Biotherapeutics posted earnings per share of ($0.27) in the same quarter last year, which indicates a negative year over year growth rate of 55.6%. The firm is expected to issue its next earnings results on Wednesday, February 26th.
According to Zacks, analysts expect that Iovance Biotherapeutics will report full year earnings of ($1.50) per share for the current financial year, with EPS estimates ranging from ($1.53) to ($1.47). For the next fiscal year, analysts forecast that the company will post earnings of ($1.70) per share, with EPS estimates ranging from ($2.32) to ($0.61). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Iovance Biotherapeutics.
Iovance Biotherapeutics (NASDAQ:IOVA) last issued its earnings results on Monday, November 4th. The biotechnology company reported ($0.40) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.01).
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC acquired a new stake in shares of Iovance Biotherapeutics during the 2nd quarter valued at $29,000. Aperio Group LLC acquired a new stake in shares of Iovance Biotherapeutics during the 2nd quarter valued at $86,000. Meeder Asset Management Inc. boosted its holdings in shares of Iovance Biotherapeutics by 453.2% during the 3rd quarter. Meeder Asset Management Inc. now owns 6,356 shares of the biotechnology company’s stock valued at $116,000 after acquiring an additional 5,207 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its holdings in shares of Iovance Biotherapeutics by 14.9% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 7,700 shares of the biotechnology company’s stock valued at $189,000 after acquiring an additional 1,000 shares in the last quarter. Finally, Prudential Financial Inc. acquired a new stake in shares of Iovance Biotherapeutics during the 2nd quarter valued at $212,000. 97.27% of the stock is currently owned by institutional investors.
Shares of IOVA stock traded down $0.15 during trading hours on Friday, reaching $24.72. The company’s stock had a trading volume of 1,079,985 shares, compared to its average volume of 1,397,611. The firm’s 50 day simple moving average is $21.94 and its 200-day simple moving average is $21.19. The company has a market capitalization of $3.12 billion, a price-to-earnings ratio of -19.46 and a beta of 1.99. Iovance Biotherapeutics has a fifty-two week low of $7.26 and a fifty-two week high of $26.59. The company has a quick ratio of 10.61, a current ratio of 10.61 and a debt-to-equity ratio of 0.02.
Iovance Biotherapeutics Company Profile
Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.
Featured Story: What moving averages are used to define a golden cross?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.